"IL-12 Stimulation But Not B7 Expression Increases Melanoma Killing by Patient Cytotoxic T Lymphocytes (CTL)."

According to the authors' abstract of an article published in Clinical and Experimental Immunology, "Recent studies have demonstrated that rodent tumour cells engineered to secrete a variety of cytokines, or to express foreign antigens, MHC molecules or co-stimulatory molecules, are rejected by syngeneic animals. These observations have led to the initiation of a number of clinical trials using genetically modified tumour cells, to attempt to stimulate a patient anti-tumour immune response. In this study, a protocol has been developed to test in vitro the specific cytotoxic anti-tumour response generated from melanoma patient lymphocytes. The results showed that IL-12 in combination...

Want to see the full article?

• Purchase this article for only $3.00